Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Chemical Synapses01:26

Chemical Synapses

9.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

756
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
756
Muscle Contraction01:10

Muscle Contraction

6.9K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems.

Arquivos de neuro-psiquiatria·2026
Same author

The weight of genotype on the clinical presentation of COQ7-related hereditary motor axonal neuropathy: a case series and literature review.

Arquivos de neuro-psiquiatria·2026
Same author

Neurological symptoms and physical exam findings 6-11 months post-COVID-19: a cohort study.

Scientific reports·2026
Same author

Cervical radiculopathy for neurologists: the role of electrodiagnosis.

Arquivos de neuro-psiquiatria·2025
Same author

Radial motor nerve conduction study in posterior interosseous nerve syndrome and multifocal motor neuropathy.

Arquivos de neuro-psiquiatria·2025
Same author

A great simulator in clinical practice: mononeuritis multiplex in HIV infection.

Autopsy & case reports·2024

Related Experiment Video

Updated: Sep 1, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Myasthenia gravis in clinical practice.

Eduardo de Paula Estephan1,2,3, José Pedro Soares Baima1, Antonio Alberto Zambon1

  • 1Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil.

Arquivos De Neuro-Psiquiatria
|August 17, 2022
PubMed
Summary

Myasthenia gravis is a treatable neuromuscular disease characterized by fatigable muscle weakness. Early diagnosis and tailored treatment, including immunosuppressants, are crucial for managing symptoms and improving patient outcomes.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.5K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

883

Related Experiment Videos

Last Updated: Sep 1, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.5K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

883

Area of Science:

  • Neurology
  • Immunology

Background:

  • Myasthenia gravis is a treatable condition with potential for significant morbidity and mortality.
  • Timely diagnosis and appropriate treatment are key to mitigating adverse outcomes.

Purpose of the Study:

  • To summarize practical aspects of diagnosing and treating myasthenia gravis.
  • To outline patient care strategies for myasthenic individuals.

Main Methods:

  • A non-systematic critical review was conducted.
  • The review focused on summarizing practical aspects of myasthenia gravis management.

Main Results:

  • Myasthenia gravis often involves autoantibodies against acetylcholine receptors or MuSK.
  • Electrophysiology is vital for diagnosing neuromuscular junction dysfunction.
  • Fatigable muscle weakness is the hallmark symptom, affecting various muscle groups.

Conclusions:

  • Understanding clinical and electrophysiological presentations is essential for diagnosis.
  • Specific treatments and response times are critical for effective patient care.